*Group B increases representation of participants who are homozygous for APOE4 to ~2x that of the general AD population.
AD, Alzheimer’s disease; APOE4, apolipoprotein E4; CSF, cerebrospinal fluid; MMSE, Mini-Mental State Examination; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; SC, subcutaneous.
1. ASCENT Clinical Trials. Accessed July 2024. https://ascent-ad.com/for-healthcare-providers/; 2. Swanson C, et al. Poster presentation at AAIC 2024; July 28-August 1, 2024; Philadelphia, PA, USA.